Imidafenacin cas number is 170105-16-5,which is a new type of diphenylbutyramide anticholinergic drug jointly developed by Ono Pharmaceutical Co., Ltd. and Kyorin Pharmaceutical. It has high bladder selectivity and is used for the treatment of overactive bladder. It was launched in Japan in June 2007. Imidafenacin cas number 170105-16-5has a diphenylbutanamide structure and is a novel high-efficiency anticholinergic drug that selectively acts on the M3 and M1 receptors, blocks the contraction of choline on the detrusor, and relaxes the detrusor. 2 times a day, each time taking 0.1mg of Imidafenacin,it can significantly improve the symptoms of urgency, frequent urination, urinary dysfunction caused by overactive bladder. Imidafenacin has the dual effects of inhibiting contraction of bladder smooth muscle and inhibiting acetylcholine freeness, and its selectivity to bladder is stronger than that of salivary gland. It has lower affinity for choline receptors in brain tissue, so there are fewer central and peripheral adverse reactions.
The new tolerance and safety of Imidafenacin is significantly better than that of propiverine and other drugs, and the very low dose can achieve the desired effect. In the new preparation of Imidafenacin, the content in the unit dose is very small, and the 0.1mg specification is commonly used in clinical practice. Since the new specification of Imidafenacin is very small, the content uniformity should be paid attention to during the production process; Oxidative degradation of impurities is apt to occur under high temperature conditions, so the formation of the oxidized impurities can be reduced by avoiding the drying process, reducing the drying time, or isolating the air during the preparation of the sample.

Imidafenacin 170105-16-5 is a new type of diphenylbutanamide anticholinergic drugs, with a high degree of bladder selectivity for overactive bladder. Bladder hyperactivity is a sign of urgency characterized by frequent urination and nocturia, with or without urge incontinence. Detrusor instability is one of the important causes of overactive bladder. Detrusor muscle has the distribution of the M receptor, so detrusor contraction control by choline. Imazapril has the effect of diphenylbutanamide, which blocks the contraction of the detrusor and inhibits detrusor relaxation. Taking Imidafenacin can significantly improve urinary frequency, urinary incontinence and other symptoms. it also has a role in inhibiting bladder smooth muscle contraction and inhibition of acetylcholine free dual effects, and the selectivity of the bladder is stronger than the salivary glands.

Thera. Category: Anticholinergic

Cas No.:170105-16-5

Synonym:ONO 8025;Staybla;Uritos;1H-IMidazole-1-butanaMide,2-Methyl-a,a-diphenyl-;4-(2-METHYL-1H-IMIDAZOL-1-YL)-2,2-DIPHENYLBUTANAMIDE;Imidafenacin;2-Methyl-α,α-diphenyl-1H-iMidazole-1-butanaMide;4-(2-Methyl-1-iMidazolyl)-2,2- diphenylbutanaMide;

Molecular Formula:C20H21N3O

Molecular Weight:319.4

Assay: ≥99.%

Packing: Export worthy packing

Material Safety Data Sheet: Available on request